- Home
- NBTX vs ATOS Comparison
NBTX vs ATOS Comparison
Compare NBTX & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- ATOS
- Stock Information
- Founded
- NBTX 2003
- ATOS 2009
- Country
- NBTX France
- ATOS United States
- Employees
- NBTX N/A
- ATOS N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- ATOS Health Care
- Exchange
- NBTX Nasdaq
- ATOS Nasdaq
- Market Cap
- NBTX 201.9M
- ATOS 174.8M
- IPO Year
- NBTX 2020
- ATOS 2012
- Fundamental
- Price
- NBTX $3.83
- ATOS $1.19
- Analyst Decision
- NBTX Strong Buy
- ATOS Strong Buy
- Analyst Count
- NBTX 2
- ATOS 3
- Target Price
- NBTX $11.50
- ATOS $6.75
- AVG Volume (30 Days)
- NBTX 8.8K
- ATOS 738.2K
- Earning Date
- NBTX 11-26-2024
- ATOS 11-12-2024
- Dividend Yield
- NBTX N/A
- ATOS N/A
- EPS Growth
- NBTX N/A
- ATOS N/A
- EPS
- NBTX N/A
- ATOS N/A
- Revenue
- NBTX $45,220,186.00
- ATOS N/A
- Revenue This Year
- NBTX N/A
- ATOS N/A
- Revenue Next Year
- NBTX N/A
- ATOS N/A
- P/E Ratio
- NBTX N/A
- ATOS N/A
- Revenue Growth
- NBTX 526.17
- ATOS N/A
- 52 Week Low
- NBTX $3.57
- ATOS $0.70
- 52 Week High
- NBTX $8.96
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- NBTX 38.67
- ATOS 31.91
- Support Level
- NBTX $3.57
- ATOS $1.26
- Resistance Level
- NBTX $4.11
- ATOS $1.66
- Average True Range (ATR)
- NBTX 0.28
- ATOS 0.09
- MACD
- NBTX -0.00
- ATOS -0.03
- Stochastic Oscillator
- NBTX 26.31
- ATOS 4.08
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.